Stock Analiz

Wave Life Sciences, Inc. WVE

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$3.13Market cap $617M
Open the interactive analysis →

Wave Life Sciences, Inc. (WVE) is a healthcare company listed in the US with a market value of about $617M. In the twelve months to September 30, 2026 it had revenue of $71M and net income of -$211M, a net margin of -296.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 16% a year, a 5-year average ROIC of -96%.

About Wave Life Sciences

Wave Life Sciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $152000 in 2015 to $43M in 2025, growth of about 75.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 114% over three years (dilution for shareholders). It spends 428% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S8.7
P/B1.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-33.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-60.6%
Revenue growth (5 yrs, per year)16.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1070.4%
ROIC (5-yr avg.)-96.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$71M$43M$108M$113M$4M$41M$20M$16M$14M$4M$1M
Net income-$211M-$204M-$97M-$58M-$162M-$122M-$150M-$194M-$147M-$102M-$56M
Free cash flow-$208M-$188M-$152M-$21M-$129M-$90M-$117M-$192M-$33M-$103M-$37M
EPS (diluted)$-1.06$-1.21$-0.70$-0.54$-2.05$-2.36$-3.82$-5.72$-5.06$-3.85$-2.44
Net margin-296.9%-478.3%-89.6%-50.8%-4434.7%-298.4%-746.7%-1211.5%-1017.4%-2619.6%-3748.1%
ROIC—-40.2%-47.0%-93.7%—-203.2%-136.1%-216.4%-115.9%-57.9%-32.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 19 analysts is $16.63, 431% above the current price; targets range from $10.00 to $44.00; the consensus rating is “Strong buy”; expected EPS is $-1.10 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Wave Life Sciences pay a dividend?

Not currently.

Is Wave Life Sciences a good stock to buy?

We do not give buy or sell advice. Wave Life Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.